to Acute and Chronic Illnesses
A New Treatment Option for Serious Fungal Infections
For decades, recurrent vulvovaginal candidasis has been a poorly managed disease process treated by ineffective treatments indicated for non-recurrent infections. Thanks to years of groundbreaking research, our lead asset is poised to provide a first-in-class solution to not only this disease, but also to systemic fungal infections in immunocompromised patients.
Providing Solutions to Antibiotic Resistance in Bacteria
Prevalence of antibiotic resistant bacteria has been increasing at the same time as the rate of antibiotic discovery has been declining. With our second asset we are a part of a resurgence in antibiotic discovery, providing a new solution to systemic bacterial infections, including those caused by MRSA. With this therapeutic compound, we can reduce mortality and morbidity associated with many emerging antibiotic resistant infections.
Sano Chemicals by the Numbers
Million dollars raised
Indications under development
Personnel, Advisors and Directors